Management of the australianclinicaltrials.gov.au website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal. Users should note that email notifications coming from the website will come from australianclinicaltrials@health.gov.au from Friday the 8th of April 2022. Any user experiencing difficulty as a result of this change should direct enquiries to australianclinicaltrials@health.gov.au for assistance.
Broad Health Condition Cancer
Cardiovascular
Specific Health ConditionMyeloma
Other cardiovascular diseases
Recruitment statusRecruiting
Recruitment Details
Recruitment State
NSW
Hospital
St Vincent's Hospital (Darlinghurst) - Darlinghurst
Postcode
2010 - Darlinghurst
Has the study received ethics approval?Approved
Trial summary
This study aims to investigate the safety and efficacy of autologous stem cell transplantation in AL amyloid patients with advanced cardiac disease. after a orthotopic heart transplantation. Who is it for? You may be eligible to join this study if you are aged between 18-65 years and have been diagnosed with cardiac AL amyloidosis. Study details All participants in this study are required to have previously received chemotherapy and a orthotopic heart transplantation before being enrolled in the study to received an autologous stem cell transplantation. Patients will undergo autologous stem cell transplantation (ASCT) within 3-6 months after OHT. patient will have an Autologous stem cell transplant using Melphalan 200mg/m2 on day -1 with stem cell collected given on day 0 previously from the patient before the study. All participants will be followed up every 3 to 6 months for a period of 5 years, in order to assess survival, and safety and efficacy of treatment. This pilot study will determine if treating patient with a stem cell transplant with cardiac amyloid after receiving a heart transplant will increase disease free survival
Key inclusion criteria
1. Cardiac AL Amyloidosis, Stage III (a) or (b) prior to heart transplantation 2. received orthotopic heart transplantation 3. adequate cardiac function: Ejection fraction > 50%, no restrictive cardiomyopathy in echocardiogram or cardiac MRI 4. absence of cardiac rejection 5. no evidence of amyloid infiltration to the cardiac allograft 6. Measurable light chains prior to induction chemotherapy (FLC > 1.5xULN with abnormal kappa:lambda ratio) 7. Measureable NT-ProBNP and Troponin-T prior to induction chemotherapy 8. ECOG status of less than 2 or Karnofsky score less than 60 (see appendix B) 9. Able to provide informed consent
Minimum age18 Years
Maximum age65 Years
GenderBoth males and females
Can Healthy volunteers participate?No
Key exclusion criteria
1. Amyloidosis other than AL Amyloidosis. This includes AA amyloidosis, senile amyloidosis, heritable amyloidosis (including but not limited to transerythin (ATTR) cardiac amyloidosis). Patients will require a negative genetic screen for heritable amyloidosis at Westmead Hospital Amyloid unit. 2. Diagnosis of multiple myeloma with more than 20% bone marrow plasma cells with end-organ involvement 3. Diagnosis of other haematological or solid organ malignancies 4. Other Amyloidosis-related end-organ diseases including renal disease (creatinine greater than 2x ULN), hepatic failure (AST, ALT greater than 3x ULN, Bilirubin > 2x ULN) 5. Significant cytopenias: Haemoglobin level <80g/L, neutrophil count <1x109/L, platelet count <75x109/L 6. Hepatitis B, C or HIV seropositivity 7. Pregnancy or breastfeeding 8. Patient with other serious medical or psychiatric illness likely to interfere with participation in this clinical study 9. Greater than grade 1 peripheral neuropathy 10. Smoking or intravenous drug use within 6 months of potential cardiac transplant
Sponsor Primary Sponsor Type: Hospital
Primary Sponsor Name: St Vincent's Hospital Sydney
Primary Sponsor Address: 390 Victoria St,
Darlinghurst NSW 2010
Primary Sponsor Country: Australia
Trial IDACTRN12617000215325
Contact person for information and recruitmentDr
Kris Ma
St Vincent's Hospital, Sydney
390 Victoria St
Darlinghurst NSW 2010
+61 2 9355 5656
+61 2 9355 5735SVHS.CancerResearch@svh.org.au
Australia